{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T10:25:54Z","timestamp":1648549554211},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,3,22]],"date-time":"2009-03-22T00:00:00Z","timestamp":1237680000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s11899-009-0009-2","type":"journal-article","created":{"date-parts":[[2009,3,21]],"date-time":"2009-03-21T05:45:21Z","timestamp":1237614321000},"page":"59-65","source":"Crossref","is-referenced-by-count":8,"title":["Predicting the response of CML patients to tyrosine kinase inhibitor therapy"],"prefix":"10.1007","volume":"4","author":[{"given":"Deborah L.","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,22]]},"reference":[{"key":"9_CR1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","volume":"36","author":"J. Groffen","year":"1984","unstructured":"Groffen J, Stephenson JR, Heisterkamp N, et al.: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984, 36:93\u201399.","journal-title":"Cell"},{"key":"9_CR2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/299747a0","volume":"299","author":"N. Heisterkamp","year":"1982","unstructured":"Heisterkamp N, Groffen J, Stephenson JR, et al.: Chromosomal localization of human cellular homologues of two viral oncogenes. Nature 1982, 299:747\u2013749.","journal-title":"Nature"},{"key":"9_CR3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","volume":"300","author":"A. Klein de","year":"1982","unstructured":"de Klein A, van Kessel AG, Grosveld G, et al.: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982, 300:765\u2013767.","journal-title":"Nature"},{"key":"9_CR4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"G.Q. Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 1990, 247:824\u2013830.","journal-title":"Science"},{"key":"9_CR5","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1073\/pnas.85.23.9312","volume":"85","author":"G.Q. Daley","year":"1988","unstructured":"Daley GQ, Baltimore D: Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr\/abl protein. Proc Natl Acad Sci U S A 1988, 85:9312\u20139316.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"T.G. Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079\u20131082.","journal-title":"Science"},{"key":"9_CR7","first-page":"100","volume":"56","author":"E. Buchdunger","year":"1996","unstructured":"Buchdunger E, Zimmermann J, Mett H, et al.: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996, 56:100\u2013104.","journal-title":"Cancer Res"},{"key":"9_CR8","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"B.J. Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038\u20131042.","journal-title":"N Engl J Med"},{"key":"9_CR9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"B.J. Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031\u20131037.","journal-title":"N Engl J Med"},{"key":"9_CR10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"S.G. O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"9_CR11","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","volume":"17","author":"S. Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Harper A, et al.: Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003, 17:2401\u20132409.","journal-title":"Leukemia"},{"key":"9_CR12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M. Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, et al.: Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809\u20131820.","journal-title":"Blood"},{"key":"9_CR13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"J.E. Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, et al.: Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 1984, 63:789\u2013799.","journal-title":"Blood"},{"key":"9_CR14","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J. Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, et al.: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998, 90:850\u2013858.","journal-title":"J Natl Cancer Inst"},{"key":"9_CR15","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/cncr.11629","volume":"98","author":"J. Cortes","year":"2003","unstructured":"Cortes J, Talpaz M, O\u2019Brien S, et al.: Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003, 98:1105\u20131113.","journal-title":"Cancer"},{"key":"9_CR16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0037-1963(03)70038-9","volume":"40","author":"J. Hasford","year":"2003","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, et al.: Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy. Semin Hematol 2003, 40:4\u201312.","journal-title":"Semin Hematol"},{"key":"9_CR17","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","volume":"84","author":"R. Hehlmann","year":"1994","unstructured":"Hehlmann R, Heimpel H, Hasford J, et al.: Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994, 84:4064\u20134077.","journal-title":"Blood"},{"key":"9_CR18","first-page":"1117","volume":"88","author":"F. Cervantes","year":"2003","unstructured":"Cervantes F, Hernandez-Boluda JC, Steegmann JL, et al.: Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica 2003, 88:1117\u20131122.","journal-title":"Haematologica"},{"key":"9_CR19","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"T.P. Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423\u20131432.","journal-title":"N Engl J Med"},{"key":"9_CR20","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1182\/blood-2003-01-0123","volume":"102","author":"B.J. Huntly","year":"2003","unstructured":"Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003, 102:1160\u20131168.","journal-title":"Blood"},{"key":"9_CR21","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood.V95.3.738.003k21_738_743","volume":"95","author":"P.B. Sinclair","year":"2000","unstructured":"Sinclair PB, Nacheva EP, Leversha M, et al.: Large deletions at the t(9, 22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000, 95:738\u2013743.","journal-title":"Blood"},{"key":"9_CR22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1365-2141.2000.02142.x","volume":"110","author":"C. Herens","year":"2000","unstructured":"Herens C, Tassin F, Lemaire V, et al.: Deletion of the 5\u2032-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients. Br J Haematol 2000, 110:214\u2013216.","journal-title":"Br J Haematol"},{"key":"9_CR23","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2002-09-2763","volume":"102","author":"B.J. Huntly","year":"2003","unstructured":"Huntly BJ, Guilhot F, Reid AG, et al.: Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003, 102:2205\u20132212.","journal-title":"Blood"},{"key":"9_CR24","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood-2004-06-2208","volume":"105","author":"A. Quintas-Cardama","year":"2005","unstructured":"Quintas-Cardama A, Kantarjian H, Talpaz M, et al.: Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005, 105:2281\u20132286.","journal-title":"Blood"},{"key":"9_CR25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/gcc.10056","volume":"34","author":"I.F. Loncarevic","year":"2002","unstructured":"Loncarevic IF, Romer J, Starke H, et al.: Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9, 22) and variants of standard t(9, 22) in BCR-ABL1-positive chronic myeloid leukemia. Genes Chromosomes Cancer 2002, 34:193\u2013200.","journal-title":"Genes Chromosomes Cancer"},{"key":"9_CR26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bjc.1981.146","volume":"44","author":"A.M. Potter","year":"1981","unstructured":"Potter AM, Watmore AE, Cooke P, et al.: Significance of non-standard Philadelphia chromosomes in chronic granulocytic leukaemia. Br J Cancer 1981, 44:51\u201354.","journal-title":"Br J Cancer"},{"key":"9_CR27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2141.2003.04291.x","volume":"121","author":"A.G. Reid","year":"2003","unstructured":"Reid AG, Huntly BJ, Grace C, et al.: Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol 2003, 121:419\u2013427.","journal-title":"Br J Haematol"},{"key":"9_CR28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2141.2004.04899.x","volume":"125","author":"M.M. El-Zimaity","year":"2004","unstructured":"El-Zimaity MM, Kantarjian H, Talpaz M, et al.: Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 2004, 125:187\u2013195.","journal-title":"Br J Haematol"},{"key":"9_CR29","first-page":"2177","volume":"8","author":"H.M. Kantarjian","year":"2002","unstructured":"Kantarjian HM, Talpaz M, O\u2019Brien S, et al.: Imatinib mesylate for Philadelphia chromosome-positive, chronicphase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002, 8:2177\u20132187.","journal-title":"Clin Cancer Res"},{"key":"9_CR30","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/sj.leu.2402996","volume":"17","author":"D. Marin","year":"2003","unstructured":"Marin D, Marktel S, Bua M, et al.: Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia 2003, 17:1448\u20131453.","journal-title":"Leukemia"},{"key":"9_CR31","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.leu.2403277","volume":"18","author":"H. Kantarjian","year":"2004","unstructured":"Kantarjian H, Cortes J: Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group. Leukemia 2004, 18:650.","journal-title":"Leukemia"},{"key":"9_CR32","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A. Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, et al.: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190\u20132196.","journal-title":"Leukemia"},{"key":"9_CR33","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","volume":"106","author":"D. White","year":"2005","unstructured":"White D, Saunders V, Lyons AB, et al.: In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005, 106:2520\u20132526.","journal-title":"Blood"},{"key":"9_CR34","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J. Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, Pirmohamed M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104:3739\u20133745.","journal-title":"Blood"},{"key":"9_CR35","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","volume":"106","author":"L.C. Crossman","year":"2005","unstructured":"Crossman LC, Druker BJ, Deininger MW, et al.: hOCT 1 and resistance to imatinib [comment]. Blood 2005, 106:1133\u20131134, author reply 1134.","journal-title":"Blood"},{"key":"9_CR36","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","volume":"83","author":"L. Wang","year":"2008","unstructured":"Wang L, Giannoudis A, Lane S, et al.: Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008, 83:258\u2013264.","journal-title":"Clin Pharmacol Ther"},{"key":"9_CR37","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"D.L. White","year":"2007","unstructured":"White DL, Saunders VA, Dang P, et al.: Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007, 110:4064\u20134072.","journal-title":"Blood"},{"key":"9_CR38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10254-003-0017-x","volume":"150","author":"H. Koepsell","year":"2003","unstructured":"Koepsell H, Schmitt BM, Gorboulev V: Organic cation transporters. Rev Physiol Biochem Pharmacol 2003, 150:36\u201390.","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"9_CR39","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2004-02-0711","volume":"104","author":"H.M. Kantarjian","year":"2004","unstructured":"Kantarjian HM, Cortes JE, O\u2019Brien S, et al.: Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-{alpha}. Blood 2004, 104:1979\u20131988.","journal-title":"Blood"},{"key":"9_CR40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(90)90601-A","volume":"60","author":"K.M. Call","year":"1990","unstructured":"Call KM, Glaser T, Ito CY, et al.: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms\u2019 tumor locus. Cell 1990, 60:509\u2013520.","journal-title":"Cell"},{"key":"9_CR41","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1038\/sj.leu.2402675","volume":"16","author":"D. Cilloni","year":"2002","unstructured":"Cilloni D, Gottardi E, De Micheli D, et al.: Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002, 16:2115\u20132121.","journal-title":"Leukemia"},{"key":"9_CR42","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/cncr.20457","volume":"101","author":"D. Cilloni","year":"2004","unstructured":"Cilloni D, Messa F, Gottardi E, et al.: Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer 2004, 101:979\u2013988.","journal-title":"Cancer"},{"key":"9_CR43","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S. Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, et al.: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496\u20133499.","journal-title":"Blood"},{"key":"9_CR44","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"R.A. Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, et al.: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022\u20134028.","journal-title":"Blood"},{"issue":"2Suppl3","key":"9_CR45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/shem.2003.50044","volume":"40","author":"T. Hughes","year":"2003","unstructured":"Hughes T, Branford S: Molecular monitoring of chronic myeloid leukemia. Semin Hematol 2003, 40(2 Suppl 3):62\u201368.","journal-title":"Semin Hematol"},{"key":"9_CR46","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1200\/JCO.2006.09.9499","volume":"25","author":"D. White","year":"2007","unstructured":"White D, Saunders V, Grigg A, et al.: Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007, 25:4445\u20134451.","journal-title":"J Clin Oncol"},{"key":"9_CR47","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T. O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500\u20134505.","journal-title":"Cancer Res"},{"key":"9_CR48","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","volume":"94","author":"E. Weisberg","year":"2006","unstructured":"Weisberg E, Manley P, Mestan J, et al.: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006, 94:1765\u20131769.","journal-title":"Br J Cancer"},{"key":"9_CR49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E. Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129\u2013141.","journal-title":"Cancer Cell"},{"key":"9_CR50","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","volume":"108","author":"D.L. White","year":"2006","unstructured":"White DL, Saunders VA, Dang P, et al.: OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006, 108:697\u2013704.","journal-title":"Blood"},{"key":"9_CR51","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","volume":"14","author":"D.K. Hiwase","year":"2008","unstructured":"Hiwase DK, Saunders V, Hewett D, et al.: Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008, 14:3881\u20133888.","journal-title":"Clin Cancer Res"},{"key":"9_CR52","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","volume":"112","author":"A. Giannoudis","year":"2008","unstructured":"Giannoudis A, Davies A, Lucas CM, et al.: Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008, 112:3348\u20133354.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0009-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-009-0009-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0009-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T00:32:55Z","timestamp":1589675575000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-009-0009-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,22]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["9"],"URL":"https:\/\/doi.org\/10.1007\/s11899-009-0009-2","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,22]]}}}